GC-012F is under clinical development by Gracell Biotechnologies and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GC-012F’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GC-012F overview
GC0-12 is under development for the treatment of advanced relapsed/refractory multiple myeloma, newly diagnosed multiple myeloma, B-cell non-Hodgkin's lymphoma, primary mediastinal b-cell lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, marginal zone b-cell lymphoma, mantle cell lymphoma and systemic lupus erythematosus. The therapy constitutes of genetically manipulated T cells which express dual chimeric antigen receptor targeting tumor cells expressing B-cell maturation antigen (BCMA) and CD19 chimeric antigen receptors. It is developed based on FasTCAR platform. It is administered through intravenous route.
Gracell Biotechnologies overview
Gracell Biotechnology Shanghai Co Ltd operates as a biopharmaceutical company. The Company develops cellular therapeutics and other biotechnology. The company is headquartered in China.
For a complete picture of GC-012F’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
